Faron Pharmaceuticals Oy (DI) (FARN) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Mar 2024 07:00 AM
RNS
Issue of Warrants to IPF Funding Update
26 Mar 2024 10:00 AM
RNS
Faron´s Annual Report 2023
18 Mar 2024 07:00 AM
RNS
Additional Positive Data from Phase 1 of BEXMAB
14 Mar 2024 07:00 AM
RNS
Faron to Host BEXMAB Webcast
13 Mar 2024 02:00 PM
RNS
Notice of Annual General Meeting 2024
13 Mar 2024 07:00 AM
RNS
Financial Statement January 1 to December 31 2023
04 Mar 2024 07:00 AM
RNS
Binding commitments for convertible loans
28 Feb 2024 04:00 PM
RNS
Replacement - Update to 2024 Financial Calendar
27 Feb 2024 06:00 PM
RNS
Update to Faron’s Financial Calendar for 2024
21 Feb 2024 02:00 PM
RNS
Continued Negotiations Regarding Events of Default
19 Feb 2024 10:30 AM
RNS
Events of Default
31 Jan 2024 07:00 AM
RNS
Further re: Exercise of options
25 Jan 2024 07:00 AM
RNS
BEXMAB Insights into Patient Profiles
19 Jan 2024 01:00 PM
RNS
Exercise of options - Issue of equity
09 Jan 2024 07:00 AM
RNS
First Patient Dosed in Ph 2 of the BEXMAB Trial
03 Jan 2024 07:00 AM
RNS
Presentation at J.P. Morgan Healthcare Conference
22 Dec 2023 07:00 AM
RNS
Faron’s Financial Calendar for 2024
11 Dec 2023 07:00 AM
RNS
Phase 1 BEXMAB data presented at ASH
07 Dec 2023 07:00 AM
RNS
MATINS Trial in Cell Reports Medicine
04 Dec 2023 07:00 AM
RNS
Grant of options
06 Nov 2023 08:13 AM
RNS
Faron Initiates Phase 2 Part of BEXMAB Study
06 Nov 2023 07:00 AM
RNS
Faron Initiates Phase 2 Part of BEXMAB Study
02 Nov 2023 01:00 PM
RNS
Faron to present data from BEXMAB study at ASH
27 Oct 2023 01:00 PM
RNS
Manager's transactions
27 Oct 2023 07:15 AM
RNS
Exercise of options
27 Oct 2023 07:00 AM
RNS
Results of Placing
26 Oct 2023 04:30 PM
RNS
Proposed Issue and Placing
11 Oct 2023 07:00 AM
RNS
Faron Announces Positive BEXMAB Study Update
03 Oct 2023 07:00 AM
RNS
Faron to host webcast on new BEXMAB study data
22 Sep 2023 04:00 PM
RNS
Board Changes
22 Sep 2023 11:00 AM
RNS
Results of EGM
21 Sep 2023 07:00 AM
RNS
Faron Appoints Interim Chief Medical Officer
08 Sep 2023 07:00 AM
RNS
Change in the Board of Directors
06 Sep 2023 07:00 AM
RNS
Faron to Present at H.C. Wainwright Conference
01 Sep 2023 10:00 AM
RNS
Notice of EGM
31 Aug 2023 02:00 PM
RNS
Exercise of options
29 Aug 2023 07:01 AM
RNS
Faron 2023 Half-Year Financial Results
29 Aug 2023 07:00 AM
RNS
FDA Orphan Drug Designation for Bexmarilimab
04 Aug 2023 07:00 AM
RNS
Notice of Half-Year Financial Results
02 Aug 2023 07:00 AM
RNS
Faron to Participate at Canaccord Conference
25 Jul 2023 07:00 AM
RNS
Grant of Options
19 Jul 2023 07:01 AM
RNS
Faron to Hold BEXMAB Study Conference Call
19 Jul 2023 07:00 AM
RNS
BEXMAB study update
30 Jun 2023 04:52 PM
RNS
Holding(s) in Company
29 Jun 2023 07:00 AM
RNS
Announcement of Placing
12 Jun 2023 07:00 AM
RNS
Exercise of options
09 Jun 2023 08:00 AM
RNS
New biomarker data from BEXMAB study at EHA2023
05 Jun 2023 07:00 AM
RNS
Board Member to Assume Transactional Advisor Role
24 Apr 2023 07:00 AM
RNS
Bexmarilimab Efficacy and Safety in MATINS Trial
24 Apr 2023 07:00 AM
RNS
Bexmarilimab Efficacy and Safety in MATINS Trial
UK 100